{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:10:34Z","timestamp":1794967834052,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.euroneuro.2023.07.011","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:30:41Z","timestamp":1691415041000},"page":"61-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies"],"prefix":"10.1016","volume":"76","author":[{"given":"Natacha","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Langlest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8061-1167","authenticated-orcid":false,"given":"Luc","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6280-2197","authenticated-orcid":false,"given":"Othman","family":"Sentissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Thorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-770X","authenticated-orcid":false,"given":"Federico","family":"Seragnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-1439","authenticated-orcid":false,"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-5596","authenticated-orcid":false,"given":"Michel","family":"Sab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.07.011_bib0001","article-title":"Side effect profiles of selective serotonin reuptake inhibitors: a cross-sectional study in a naturalistic setting","volume":"23","author":"Anagha","year":"2021","journal-title":"Prim. Care Compan. CNS Disord."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0002","series-title":"Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123255","article-title":"MDMA for the treatment of negative symptoms in schizophrenia","volume":"11","author":"Arnovitz","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0004","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0006","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0007","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0008","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0009","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0012","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0013","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0014","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/wps.20881","article-title":"Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review","volume":"20","author":"Correll","year":"2021","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0015","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0016","article-title":"One-stage dose\u2013response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0018","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0019","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, Psilocybin, MDMA, and ketamine","volume":"41","author":"De Gregorio","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0020","article-title":"User's guide for the SCID-5-CV structured clinical interview for DSM-5\u00ae disorders: clinical version. User's Guid. SCID-5-CV struct","author":"First","year":"2016","journal-title":"Clin"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0021","first-page":"166","article-title":"Primary versus secondary depression: practical applications","volume":"2","author":"Florita","year":"2005","journal-title":"Clin. Neuropsychiatry J. Treat. Eval."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0023","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jadr.2021.100240","article-title":"Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies","volume":"6","author":"Gard","year":"2021","journal-title":"J. Affect. Disord. Reports"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to Meta-analysis","volume":"135","author":"Greenland","year":"1992","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0027","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0028","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","author":"Haijen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0033","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0962280220982643","article-title":"A Bayesian dose\u2013response meta-analysis model: a simulations study and application","volume":"30","author":"Hamza","year":"2021","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/0269881121992676","article-title":"Dose-response relationships of psilocybin-induced subjective experiences in humans","volume":"35","author":"Hirschfeld","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0036","unstructured":"Hofmann, A., 1980. LSD- my problem child."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0038","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis","volume":"296","author":"Li","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0040","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","article-title":"Prevalence of depression in the community from 30 countries between 1994 and 2014","volume":"8","author":"Lim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0041","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and Meta-analysis","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: practical considerations for dosing and administration","volume":"13","author":"MacCallum","year":"2022","journal-title":"Front. psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.749068","article-title":"Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder","author":"Markopoulos","year":"2022","journal-title":"Front. Pharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0044","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0046","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22r14518","article-title":"Control conditions in randomized trials of psychedelics: an ACTTION systematic review","volume":"84","author":"Nayak","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0047","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1600-0447.2011.01744.x","article-title":"The heterogeneity of the depressive syndrome: when numbers get serious","volume":"124","author":"\u00d8stergaard","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0048","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/02698811231155117","article-title":"Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors","author":"Ponomarenko","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/7854_2016_459","article-title":"Phenomenology, structure, and dynamic of psychedelic States","volume":"36","author":"Preller","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0051","series-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","year":"2019"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0052","doi-asserted-by":"crossref","first-page":"niad001","DOI":"10.1093\/nc\/niad001","article-title":"Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives","volume":"2023","author":"Rankaduwa","year":"2023","journal-title":"Neurosci. Conscious."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0053","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cpr.2011.07.004","article-title":"Prevalence and clinical course of depression: a review","volume":"31","author":"Richards","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0054","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/02698811211064720","article-title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation","volume":"36","author":"Rucker","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","article-title":"A century of research on psychedelics: a scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs","volume":"64","author":"Solmi","year":"2022","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0057","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/1516-4446-2020-0935","article-title":"How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations","volume":"43","author":"Solmi","year":"2021","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0058","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0059","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/pharmrev.121.000508","article-title":"Neural mechanisms and psychology of psychedelic ego dissolution","volume":"74","author":"Stoliker","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0061","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0063","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0064","series-title":"Depression and Other Common Mental Disorders: Global Health Estimates, World Health Organization","year":"2017"},{"key":"10.1016\/j.euroneuro.2023.07.011_bib0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23001529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23001529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:07:19Z","timestamp":1760378839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23001529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":65,"alternative-id":["S0924977X23001529"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}